FibroGen eyes rebound path with Ph1 ADC data for prostate cancer drug

Af­ter a se­ries of clin­i­cal dis­ap­point­ments, Fi­bro­Gen could be on the come­back trail with promis­ing ear­ly da­ta from a CD46-tar­get­ing an­ti­body-drug con­ju­gate de­vel­oped by part­ner For­tis Ther­a­peu­tics.

The ADC can­di­date, FG-3246, is the sub­ject of a four-year agree­ment made in May 2023 in which Fi­bro­Gen has the op­tion to buy For­tis for $80 mil­lion up­front with the biotech al­so el­i­gi­ble for up to $200 mil­lion in ap­proval-linked mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.